Aim: To investigate the enhancing effect of radionuclide therapy by the therapeutic gene placed under the control of radio-responsive promoter. Methods: The recombinant lentivirus E8-codA-GFP, including a synthetic radiation-sensitive promoter E8, cytosine deaminase (CD) gene, and green fluorescent protein gene, was constructed. 
I radiation was assessed by observation of green fluorescence. The ability of converting 5-fluorocytosine (5-FC) to 5-fluorourial (5-FU) by CD enzyme was assessed by high-performance liquid chromatography. The viability of the infected cells exposed to 125 I in the presence of 5-FC was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and the infected cells exposed to 125 I alone served as negative control and 5-FU as positive control. Results: The recombinant lentiviral vector was constructed successfully. On exposure of infected cells to 125 I, green fluorescence can be observed and 5-FU can be detected. MTT assay showed that the survival rate for infected cells treated with 125 I was lower compared with the 125 I, cytosine deaminase, radiation-sensitive promoter, recombinant lentivirus Introduction R adionuclide based therapy plays an increasingly important role in the treatment of cancer. However, its efficacy is limited for many tumors because the delivery of the curative dose of radionuclide to the tumor is frequently limited by the normal tissue tolerance, especially for myelotoxicity. Targeting therapy, including radioimmunotherapy, 1, 2 radio-receptor therapy, 3, 4 and the therapy targeting specific tumor genes, 5 which is designed to irradiate tumor cells yet minimize the radiation dose received by normal cells, is a theoretically effective therapeutic approach and has achieved considerable success in hematological malignancy (such as radiolabeled anti-CD20 in the treatment of CD20-positive non-Hodgkin's lymphomas). However, curative therapy for most of solid tumors still remains challenging. 6 Although described as a ''targeted'' treatment, it does not specifically target the tumor and the distribution in the normal organ is also frequently beyond a safety margin. Therefore, the innovative approaches with an improved therapeutic ratio are required.
One of the limiting factors to the success of radionuclidebased therapy is the radiosensitivity of the target organ. Contemporary molecular biological techniques made it possible to increase the tumor radiosensitivity through altering the genetic profile of a tumor. By transducing therapeutic genes with a radiation-sensitive promoter on the upstream into tumor cells, the tumor cells will be sensitized to radiation and the killing effect is expected to be enhanced. The concept of using a radio-responsive gene to enhance therapeutic efficacy has already been used in radiotherapy. In 1994, Boothman proposed that promoter sequences of radiation-inducible genes could be used for the controlled expression of therapeutic genes. 7 Recently, more attention focused on the combination of radiotherapy with gene therapy using the cytosine deaminase (CD) gene, 8 herpes simplex virus thymidine kinase (HSV-tk) gene, 9 and tumor necrosis factor (TNF)-a gene 10 as the therapeutic gene placed downstream of early growth response gene (Egr-1) sequences used as the radiation-responsive promoter. Tumor cells containing these genes were sensitized to the radiation at a lower dose. The results showed that the novel approach can lead to more effective tumor cell killing, induce tumor growth delay, enhance tumor growth control with relative sparing of normal tissue, and thus increase the therapeutic ratio. The Phase I/II clinical trials have been conducted with Ad.Egr.TNF-a plasmid (referred to as TNFerade) in combination with radiotherapy.
10,11 A significant tumor response was observed with no server local or systemic toxicity. Egr-1 can also be activated by the radiation of radionuclide. 12, 13 Therefore, it is to be expected that the efficacy of radionuclide-based therapy will be increased by introducing the therapeutic gene with radio-responsive promoter into tumor cells. Besides Egr-1, the synthetic radio-responsive promoter consisting of continuous repeated CC(A/T)6GG sequences (CArG elements) was also reported and shown to be more radiation sensitive than the native Egr-1 enhancer. 14 In the previous study, the authors have investigated the potential of using the 131 I-labeled anti-bladder cancer monoclonal antibody BDI-1 for radioimmunoimaging and radioimmunotherapy of bladder cancer and obtained promising results. 15, 16 To further enhance the therapeutic efficacy and minimize the damage to normal tissues, in this study, the authors construct the vector containing CD gene ligated to the synthetic radiosensitive promoter containing eight repeated CArG elements on the upstream and green fluorescent protein (GFP) coding sequence as the report gene to monitor the expression of the therapeutic gene and compare the killing efficacy of 125 I radiation on bladder cancer EJ cells infected with the vector in the presence of prodrug 5-fluorocytosine (5-FC) with 125 I radiation alone.
Materials and Methods

Cell lines and reagents
The human bladder cancer EJ cell line was purchased from the Pathology Department of Peking University and was cultured at 37°C, 5% CO 2 in monolayer culture in a complete medium comprising the RPMI 1640 culture medium supplemented with 10% fetal calf serum (FCS). All cell culture reagents were purchased from Hyclone Corporation. The pCD 2 vector was purchased from ATCC (American Type Culture Collection). 5-FC and 5-Fluorourial (5-FU) were purchased from Sigma Corporation. Liquid Na 125 I (2.22 GBq/ mL, radiochemical purity >99%) was purchased from Beijing Atom HighTech Co. Ltd.
Construction of the plasmid
Construction of pGC-FU-codA-GFP plasmids. The pCD 2 plasmid was used as the basis for the vector construction.
The primer was designed according to the CD sequence from GenBank, containing Age I sites at 5¢ end and 3¢ end, respectively. The CD gene sequence-Age I-Forward: 5¢ GAGGATCCCCGGGTACCGGTCGCCACCATGTCGAA TAACGCTTTACAAAC3¢. The CD gene sequence-Age IReward: 5¢TCACCATGGTGGCGACCGGACGTTTGTAA TCGATGGCTTC3¢. The cDNA of CD gene was obtained from the template of pCD 2 using polymerase chain reaction (PCR), and the PCR products were separated by 1.0% agarose gel electrophoresis. The purified PCR products were inserted into the lentivirus vector containing the GFP gene (pGC-FU vector; from Genechem Company) at the site of Age I. The vector was transformed into Escherichia coli strain DH5a cells preprocessed by CaCl 2 , and the transformants were selected for apramycin resistance. The positive clones were implanted into the culture media after being determined by PCR. The plasmids were extracted from the strains and named as pGC-FU-codA-GFP. The sequence of the plasmid was confirmed by sequencing.
Synthesis of the radio-responsive promoter E8 and construction of pGC-FU-E8-codA-GFP plasmid. The radioresponsive promoter E8 containing eight repeated CArG elements was engineered to contain Pac I/BamH I sites at 5¢ end and 3¢ end, respectively. The gene sequence was 5¢TTAATTAACCGCGGCCTTATTTGGCCTTATTTGGC CTTATTTGGCCTTATTTGGCCTTATTTGGCCTTATTT GGCCTTATTTGGCCTTATTTGGCCGCGGGGATCC3¢. The synthetic E8 and pGC-FU-codA-GFP were digested with Pac I/BamH I, purified, and ligated to generate the pGC-FU-E8-codA-GFP vector. The vector was transformed into E. coli strain DH5a cells preprocessed by CaCl 2 , and the transformants were selected for apramycin resistance. The positive clones were determined by PCR and implanted into the culture media. The plasmids were extracted from the strains. The sequence of the plasmid was confirmed by automatic sequencing.
The package of recombinant lentivirus. The purified pGC-FU-E8-codA-GFP reconstructed vector or empty vector pGC-FU was cotransfected with pHelper 1.0 and pHelper 2.0 vector into 293T cells using Lipofectamine 2000 for 8 hours. The supernatant of 293T cells was collected, centrifuged at 4000 g, 4°C for 10 minutes, and filtrated with a 0.45-lm filter. The recombinant lentivirus E8-codA-GFP LV or the control lentivirus GC-FU-GFP LV containing empty vector was obtained and stored at -80°C.
Measurement of the lentivirus titer. The lentivirus titer was measured by a serial dilution method. 293T cells at exponential growth phase were implanted into 24-well plates at the concentration of 1 · 10 5 cells per well. The cells were infected with the lentivirus with 10-fold dilution series from 1:10 to 1:10 6 in each well (triplicate). After cultured for 48 hours, the cells were cultured in a regular medium. Four days later, the titer of GC-FU-GFP LV was measured by evaluating the fluorescence expressed by the GFP gene. The titer of E8-codA-GFP LV was measured by real-time quantitative PCR. In brief, total RNA was extracted from the cells infected with E8-codA-GFP LV with TRIzol (Invitrogen). After synthesized by reverse transcriptase, cDNA was used as a template in PCRs. Serially diluted plasmid was CELL KILLING OF 125 I ENHANCED BY THERAPEUTIC GENEutilized to draw a standard curve. The cutoff point (Ct) of each sample was plotted on the standard curve and the mRNA copy numbers were calculated. Actin was used as an internal control.
Cell infection
The condition of lentivirus infection on EJ cells was tested using GC-FU-GFP LV in 96-well plates. The best condition was found in ENi.s (enhanced infection solution; Genechem provided) supplemented with 5-lg/mL polybrene (Genechem provided) when MOI (multiplicity of infection) was 60. EJ cells of 3 · 10 3 were plated in each well of a 96-well plate. After EJ cells were infected by E8-codA-GFP LV for 12 hours, the medium was changed to RPMI 1640 containing 10% FCS. Infected cells were cultured for 48 hours for the assessment of gene expression. Green fluorescence observation. Infected cells were irradiated as monolayers in 96-well plates by adding 18.5, 37.0, 55.5, 74.0 kBq of Na 125 I, respectively, and supplemented with the RPMI 1640 medium containing 10% FCS to 100 lL each well (n = 3). Infected cells without Na 125 I were used as controls (n = 3). After 48 hours of incubation, the radiation-induced gene expression was assessed by the observation of green fluorescence under a fluorescence microscope (Nikon eclipse TE2000-s).
Conversion of 5-FC to 5-FU. The infected cells in 96-well plates were divided into three groups (three wells each group) according to the added 125 I at the dose of 37, 74, 148 kBq, respectively. Four hundred micrograms per milliliter of 5-FC was added in each well meanwhile. As control, uninfected cells were also divided into three groups (n = 3) and added the same dose of 125 I and 5-FC. After 48 hours of radiation, the cell supernatants of the three wells in each group were mixed, and the concentration of 5-FC and 5-FU was analyzed by HPLC (high-performance liquid chromatography, Prominence LC-20A and Venusil MP C18 HPLC column, 10 · 250 mm, 5 lm) with the developing solvent consisted of acetonitrile: water = 1:9 (v/v) at the flow rate of 1 mL/min. The retain time for 5-FC and 5-FU was about 4.97 and 6.03 minutes, respectively. The absorption peak area ratio of 5-FU over 5-FC was used to estimate the conversion efficiency.
Measurement of cell survival rate
The infected cells in 96-well plates were divided into four groups, including an experimental group, a 125 I control group, a positive control group, and a negative control group. For the experimental group and 125 I control group, the cells were divided into three subgroups (three wells each group) according to the 125 I dose added. In the experimental group, 37, 74, 148 kBq of Na 125 I aq. and 400 lg/mL 5-FC were added to the above subgroups, respectively. In the 125 I control group, only 37, 74, and 148 kBq of Na 125 I aq. were added. Infected cells (three wells) with added 400 lg/mL 5-FU served as the positive control group and uninfected cells (three wells) without 125 I and 5-FC were used as the negative control group. All the cells were incubated in 5% CO 2 , 37°C, for 48 hours. The cell survival rate was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, aforementioned cells were incubated with 20 lL of MTT (5 mg/mL, in pH7.4 phosphate-buffered saline) for 3 hours at 37°C and 200 lL of dimethyl sulfoxide was added to solubilize the crystals for 20 minutes at room temperature. The plates were agitated to ensure complete mixing, and optical density (OD) was measured on a multiplate reader (microplate reader model 680) at a wavelength of 490 nm. Blank wells containing water added the same volumes of MTT solution were used as blank. The cell survival rate is expressed as (OD value of the experimental group or 125 I control group or the positive control group/OD value of the negative control group ·100%). The cell survival rate is taken as 100% when the measured OD value of the experimental group or 125 I control group or the positive control group is greater than the OD value of the negative control group.
Results
Analysis of the E8 and CD gene
The CD gene obtained by PCR using pCD 2 as template was analyzed by gel electrophoresis and found to have a length of 1327 bp (Fig. 1) . For analysis of the E8 promoter in pGC-FU-E8-codA-GFP plasmid, the plasmid was digested with Pac I/BamH I and then electrophoresed. The result showed a fragment of 96 bp corresponding to the E8 gene (Fig. 2) . Plasmid pGC-FU-E8-codA-GFP was transformed into E. coli DH5a strains and the transformants were selected for apramycin resistance, and positive clones were picked up and verified by PCR. DNA sequence of the positive transformant showed that the plasmid contains eight CC(A/T) 6 GG elements and the CD gene code, which is conformed with the X63656.1 sequence in the GenBank. The first base A in the CD gene of pGC-FU-E8-codA-GFP plasmid is different from that in the GenBank (its first base is G) because the former is obtained from the prokaryote E. coli with its start codon of GUG, 17 but in the latter, the start codon is AUG for eukaryota.
The sequence of E8 promoter is as follows: 5¢TTAAT TAACCGCGGCCTTATTTGGCCTTATTTGGCCTTATT 
The package of recombinant lentivirus
The recombinant lentivirus E8-codA-GFP LV and the lentivirus containing parental vector GC-FU-GFP LV were successfully obtained by transfecting the plasmids into 293T cells cotransfected with pHelper 1.0 and pHelper 2.0 vectors in the presence of Lipofectamine 2000. The titer of GC-FU-GFP LV and E8-codA-GFP LV was 2 · 10 9 and 2 · 10 8 TU/ mL, respectively.
GFP gene expression
The infected cells at the presence of 18.5, 37.0, 55.5, and 74.0 kBq Na 125 I for 48 hours and the controls without 125 I were observed under the fluorescence microscope. The expression of fluorescence can be seen at 125 I dose as low as 18.5 kBq and was clearer with the increased dose of 125 I in the dose range from 18.5 to 74.0 kBq (Fig. 3) . This showed that synthetic radiation-responsive promoter E8 could activate downstream GFP gene expression with the induction of low dose of into cytotoxic 5-FU, which plays an important role in tumor therapy. 18 Combination of radiotherapy with CD gene containing radio-responsive promoter in the presence of 5-FC has been proved to be an effective strategy in tumor cell killing. 19 Radionuclide can also activate radiation-sensitive promoter and then regulate the expression of suicide genes in space and time to play killing effects on tumor cells. It has been reported that 125 I-UdR can activate Egr-1 promoter and increase the antitumor effect in combination with Egr-1 promoter-based IFNc gene therapy. 12, 20 Egr-1 is the most studied radio-sensitive promoter in radiation-induced gene therapy. Weichselbaum et al. reported a 3.2-fold increase in chloramphenicol acetyltransferase (CAT) reporter gene expression in human HL252 cells in vitro and a 2.7-fold increase in SQ-20B tumor xenografts after a single 20 Gy treatment using the Egr-1 enhancer. 21 The DNA sequences that drive the IR response of Egr-1 are located in the enhancer region of the promoter. 22 These were identified as 10 nucleotide motifs of the consensus sequence CC(A/T) 6 GG, also known as CArG elements. The murine and human Egr-1 promoters contain five and four CArG elements, respectively.
To create gene therapy vectors that can be activated by lower doses of IR, synthetic enhancers containing isolated CArG elements were manufactured.
14 These promoters consist of an enhancer region containing tandemly arranged CArG 2 elements, and therefore lacked binding sites for the potentially antagonistic transcription factors that appeared in the native Egr-1 promoter, which may deregulate the expression (could restrict radio-responsiveness) under radiation. The results showed that the synthetic enhancers were more responsive to IR than the wild-type Egr-1 gene. 14, 23 An enhancer containing four isolated copies of the CArG 2 element (E4) showed 3.1-fold (-0.25) increase after IR compared with 1.86-fold (-0.2) for the native human Egr-1 counterpart after 3 Gy activation dose, and the synthetic promoters responded to radiation doses as low as 1 Gy.
14 Scott et al. tested the promoters carrying 4, 6, 9, and 12 tandem-repeat copies of the prototype CArG sequence (E4, E6, E9, and E12 enhancers) and found that increasing the number of CArG 2 elements from 4 to 6 and then 9 improved the specific IR, but the E12 promoter was less inducible than E9. 23 In this study, the promoters carrying eight tandemrepeat copies of the CArG sequence were synthesized, and the result showed that it is sensitive to low dose of 125 I. The efficient delivery of transgene to tumor sites is a key factor for successful gene therapy. It remains a formidable task, but progress has been made in recent years. Viral vectors and nonviral vectors are usually used in gene delivery systems. Major viral-based gene delivery systems are adenoviral vectors, adeno-associated viral vectors, and retroviral/lentiviral vectors. Nonviral-based delivery systems include cationic liposome, PEGylated system, HESylated system, and nanoparticle-based delivery system. 24 Viral vectors have a high transduction efficiency, but are safety concerned due to systemic toxicity and the immunogenicity induced in the host. Nonviral vectors have the advantages of nonimmunogenic, available to production on large scale and easy modification, but the transduction efficiency is relatively low. Lentivectors have been under development for use in gene therapy since the mid-1990s. Substantial effort has led to the development of the third-generation lentivectors now in use. The new generation of lentivectors has the advantages of long-term expression, cell-and tissuespecific tropism, high transduction efficiency, and large packaging capacity for the delivery of therapeutic genes. [25] [26] [27] It is reported that lentivectors were 2-10 times more effective in transducing human dendritic cells (DCs) and mouse DCs than adenovectors. 26 Recently, targeting vectors, which could be injected intravenously and bind selectively to the tumor, have been studied. Adding nonviral vectors, such as incorporating targeting peptides (EGF, RGD, APRPG) into polyethylenimine (PEI), 28 polylysine (PLL), 29 and viral vectors, such as insertion of RGD peptide into the H1 loop of the fiber knob domain in adenovirus, 30 genetically incorporates targeting peptides into adeno-associated virus capsids. 31 Each technique has advantages and disadvantages. However, it will become more and more mature with the progress of transgene technology. By combining with gene therapy containing radiosensitive promoter, the radionuclide-based therapy shows promise and a bright hopeful future in the therapy of systemic tumors.
Conclusion
In the context, the authors constructed the plasmid containing CD gene and the GFP coding sequence under the control of the synthetic promoter E8. The E8 promoter and CD gene sequence were confirmed by DNA sequencing. To monitor the gene expression, the authors used the GFP as a reporter. The cells without 125 I inducing showed no notable fluorescence, which indicated that the basal expression can be neglected. The expression of fluorescence can be seen with 125 I dose as low as 18.5 kBq, which indicated that the plasmid was very sensitive to radiation and low dose of 125 I can induce the gene expression. Similar results were reported by Zhao et al. 32 who used 125 I-UdR to irradiate Egr-1 radio-responsive promoter-controlled IFNc gene to study the in vitro radiation inducible gene expression and found that IFNc protein levels with 5, 10, 20, 50 kBq/mL doses of 125 I -UdR were obviously higher than no 125 I -UdR added group, and the gene expression levels are both dose dependent and time dependent.
The activity of CD protein can be evaluated by the conversion of 5-FC to 5-FU. The conversion efficiency can be measured either by the 3 H-5-FU tracer method 33 or by the HPLC method. 19 The authors used the HPLC method to measure the 5-FU level in the infected cell supernatants irradiated with 125 I at the dose of 37-148 kBq. The 5-FU peak can be detected even at the 125 I dose of 37 kBq and the peak area increased at the higher doses. The area ratio of 5-FU to 5-FC absorption peak was used to evaluate the conversion efficiency. The result showed that the conversion efficiency has the tendency of increasing with the increased dosage of 125 I and was at the highest when the dose of 125 I was 148 kBq at the dose range from 37 to 148 kBq. This indicated that infected EJ cells could express cytosine deaminase, which did not exist in mammalian cells, and then convert 5-FC to cytotoxic agent 5-FU and the level of expression was in a dose-dependent manner.
To detect the cell killing effect of the pGC-FU-E8-codA-GFP plasmid combined with different doses of 125 I radiation, MTT assay was performed. The result showed that the survival rates of EJ cells delivered the purpose gene irradiated I radiation at aforementioned dose had little killing effect to the EJ cells. In combination with CD gene affection, the cell survival rates were decreased to a certain extent. The result showed that the cell killing effect of 125 I radiation can be enhanced by the combined treatment with CD gene-ligated synthetic radioresponsive promoter and the corresponding prodrug 5-FC.
In these cell survival studies, the lowest cell survival rate was 65.43%, which was not strong enough to justify the translation of this approach to animal models and clinical studies. The main possible reason for this was that the 125 I and 5-FC dose did not achieve the optimized level. In radionuclide therapy, 125 I with a half-life of 59.4 days and average energy of 27.4-35.5 Kev provides a continuous lowdose rate irradiation, which has little killing effect at low dosage in the short time period.
125 I brachytherapy using 125 I seed is the most clinically used modality for 125 I therapy. The results by Ma et al. 34 and Takabayashi et al. 35 showed the radiation dose up to 2 Gy (generated by the inhouse model containing 9 125 I seeds with the surface activity of 15.3-22.2 MBq and irradiated for 44-96 hours) can reach the therapeutic level to the SW-1990 pancreatic cancer cells and gastric cancer cells. The therapeutic effect of 125 I can be significantly increased by being labeled to the targeting molecules such as ITdU, which can incorporate into DNA of the cells 36 or monoclonal antibodies binding to tumor cell surface. 37 In the dose range of 37-148 kBq in this study, 125 I radiation alone had almost no killing effect to the EJ cells. However, the therapeutic efficacy may be increased by increasing the 125 I dosage or conjugating the radionuclide to the targeting molecules. From the cell survival rate results, one can also see that the cell survival rate in the 5-FUpositive control group was lower than in the experimental group, which indicated that there was a room to increase the killing effect by increasing the conversion rate of 5-FC to 5-FU, which is also expected to be achieved by increasing the 125 I dosage and optimizing the dose of 5-FC. Thus, although the killing effect is not strong enough to reach the very effective tumor therapeutic level in this study, this result was promising since one can expect the cell survival rates will be further decreased by increasing 125 I dose to the therapeutic level and optimizing the 5-FC dose. Further research is undergoing.
